MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Scott Feinberg - Investor Relations
Maher Masoud - President & Chief Executive Officer
Doug Swirsky - Chief Financial Officer
Conference Call Participants
Matt Larew - William Blair
Julie Simmonds - Panmure Liberum
Jacob Johnson - Stephens
Paul Cuddon - Deutsche Numis
Rohan Walcott - Stifel Nicolaus & Company
Matt Hewitt - Craig-Hallum
Chad Wiatrowski - TD Cowen
Operator
Hello and welcome to MaxCyte Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to Scott Feinberg of Investor Relations. You may begin.
Scott Feinberg
Good afternoon, everyone. My name is Scott Feinberg, and I am responsible for Investor Relations here at MaxCyte. Thank you for participating in today's conference call. Joining me on the call from MaxCyte we have Maher Masoud, President and Chief Executive Officer; and Doug Swirsky, Chief Financial Officer.
Earlier today MaxCyte released financial results for the second quarter ended September 30 2024. A copy of the press release is available on the company's website.
Before we begin I need to read the following statement. Statements or comments made during this call maybe forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events results or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors, which are discussed in detail in our SEC filings. Except as required by applicable law the company has no obligation to publicly update any forward-looking statement whether because of new information future events or otherwise.
And with that I will turn over the call to Maher.
Maher Masoud
Thank you Scott. Good afternoon everyone. And thank you for joining MaxCyte's third quarter 2024 earnings call. MaxCyte reported $8.2 million of total revenue in the third quarter primarily comprised of core revenue, which exceeded our internal expectations. We were pleased with execution of our team and continued demand for our ExPERT Platform which has been further demonstrated by the six new Strategic Platform Licenses that we signed this year including one signed in the third Quarter.
A new record number of SPLs signed in a single year of the company. We have increased our expectations for core revenue growth in 2024 due to our confidence in underlying business trends we've seen over the last three quarters. The core business for MaxCyte in the third quarter performed very well particularly in cell therapy.